ARTICLE | Emerging Company Profile
Arsanis: Antibodies for infection
Arsanis developing antibodies for bacterial diseases, nosocomial infections
April 2, 2012 7:00 AM UTC
By targeting conserved sequences of bacterial proteins as well as bacterial toxins, Arsanis Inc. expects its antibody cocktails to improve outcomes in infections that are resistant to conventional antibiotics.
Arsanis was created when its three founders, one from Intercell AG, and two from Adimab LLC, realized they had complementary goals...